close

Enter

Log in using OpenID

Market Research Report On Paclitaxel Injection

embed
Paclitaxel Injection Market Opportunities: The major drivers for this market are the rising incidence of cancer globally and the improved efficacy of paclitaxel injections. However, adverse drug reactions associated with the drug as well as the eme
Global Paclitaxel Injection Market
Opportunities and Forecasts, 2013 - 2020
REPORT DESCRIPTION
The report provides market analysis, information and insights into “Paclitaxel Injection
Market ”
Paclitaxel belongs to the group of medications known as antineoplastics and is used in
the treatment of cancers. It works by inhibiting the growth of cancer cells and is used in
the treatment of various cancers such as breast cancer, ovarian cancer, non small cell lung
cancer, etc. According to the WHO, cancer was the leading cause of death worldwide,
accounting for the death of 8.2 million people in 2012. The major drivers for this market
are the rising incidence of cancer globally and the improved efficacy of paclitaxel
injections. However, adverse drug reactions associated with the drug as well as the
emergence of targeted treatment, personalized medicine and novel anti-cancer drugs
would be a challenge to the growth of this market. The opportunities for this market are
its potential to be used for treatment for various types of cancers.
View Sample [email protected] http://www.bigmarketresearch.com/paclitaxel-injection-market
KEY MARKET BENEFITS




Market segmentation by use of the product would help in identification of future
applications
Porter’s five force model helps in making strategic business decisions for business
development
In-depth geographic Analysis would aid in identifying regions where demand for this
product would increase
In-depth analysis of drivers and opportunities would help in understanding the future
potential of this market
KEY MARKET SEGMENTS
Paclitaxel Injection Market by use in treatment of various cancers
Paclitaxel Injection is used in the treatment of Breast cancer, Ovarian cancer, Non small cell
lung cancer, AIDS related Kaposi's sarcoma, Cervical Cancer, Esophageal cancer, Prostate
cancer , Stomach cancer, Testicular cancer, Lung cancer, Pancreatic cancer, and Others.
According to the WHO, stomach cancer accounted for 723,000 deaths and breast cancer
accounted for 521,000 deaths respectively in the year 2012 alone. Paclitaxel is used for the
treatment of both these cancers and the rising incidences of cancer would result in
increased use of this drug for treatment.
Paclitaxel Injection Market by Geography
Paclitaxel Injection Market is segmented geographically into North America, Europe, Asia
Pacific and RoW. Currently the market is dominated by North America due to the high
incidence of Cancer patients in this region. However, Europe and Asia Pacific are emerging
markets due to rising incidences of cancer.
MARKET OVERVIEW
Competitive analysis
The companies in this market are Abraxis Bio Science Inc., Celgene, Abbott Laboratories,
Fresenius Kabi Oncology Ltd, Onco therapies Ltd, Novasep, Sagent Pharmaceuticals and
others. The European Commission approved ABRAXANE to be taken in combination with
Gentamicin for the treatment of metastatic pancreatic cancer in January 2014.
ABRAXANE was developed by Celgene International Sàrl, a subsidiary of Celgene
Corporation.
High Level Analysis
Porter’s five force model analyzes the bargaining power of the suppliers and buyers as
well as the threat of new entrants. The threat of substitutes in this market is high, with
extensive research and development being carried out in anti-cancer drugs. SWOT
analysis helps in making strategic decisions for development and expansion. The key
drivers, restraints and opportunities are analyzed to help in better understanding the
growth of this market.
SUMMARY
Paclitaxel is used for the treatment of both these cancers and the rising incidences of cancer
would result in increased use of this drug for treatment.
The companies in this market are Abraxis Bio Science Inc., Celgene, Abbott Laboratories,
Fresenius Kabi Oncology Ltd, Onco therapies Ltd, Novasep, Sagent Pharmaceuticals and
others. The European Commission approved ABRAXANE to be taken in combination with
Gentamicin for the treatment of metastatic pancreatic cancer in January 2014. ABRAXANE
was developed by Celgene International Sàrl, a subsidiary of Celgene Corporation.
Enquiry For [email protected] http://www.bigmarketresearch.com/report-enquiry/22831
FOR MORE DETAILS
Visit us at :
www.bigmarketresearch.com
Stay With Us:
TELEPHONE: + 1-800-910-6452
EMAIL:
[email protected]
5933 NE Win Sivers Drive,
#205, Portland, OR 97220
United States
1/--pages
Report inappropriate content